Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

CD14 + CD16 + Monocyte Binding to Myeloma Cells Is Required for Daratumumab Dependent Killing in Multiple Myeloma Patients

Paola Storti, PhD, Rosanna Vescovini, PhD, Valentina Marchica, MS, Marina Bolzoni, PhD, Federica Costa, MS, Emanuela Vicario, MS, Denise Toscani, PhD, Anna Benedetta Dalla Palma, MD, Fabrizio Accardi, MD, Fabio Malavasi, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2018) 132 (Supplement 1): 3200.

https://doi.org/10.1182/blood-2018-99-112873

Published: 2018

Journal Articles

Daratumumab Mitigates B-Cell Receptor Signaling and Enhances Antitumor Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL) Cells

Alak Manna, PhD, Sharoon Akhtar, MPhil, Zahara Meghji, Kirtipal Bhatia, Paul Yi, BS, Sameer A. Parikh, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Taimur Sher, MD, Fabio Malavasi, MD, Victoria R. Alegria, Sikander Ailawadhi, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2017) 130 (Supplement 1): 3019.

https://doi.org/10.1182/blood.V130.Suppl_1.3019.3019

Published: 2017

Journal Articles

Precision Targeting of Ion Channel Blocker for the Treatment of AML

David Marshall, BS, Antonella Chillemi, PhD, Fabio Malavasi, MD, James Prudent, PhD

Blood (2017) 130 (Supplement 1): 5203.

https://doi.org/10.1182/blood.V130.Suppl_1.5203.5203

Published: 2017

Journal Articles

Targeting CD38 with Daratumumab Suppresses B-Cell Receptor Signaling and Enhances the Activity of Ibrutinib in Waldenstrom Macroglobulinemia Cells

Aneel Paulus, MD, Alak Manna, PhD, Sharoon Akhtar, MPhil, Taimur Sher, MD, Vivek Roy, MD, Morton Coleman, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD, Fabio Malavasi, MD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 1529.

https://doi.org/10.1182/blood.V130.Suppl_1.1529.1529

Published: 2017

Journal Articles

Daratumumab Decreases Treg-Mediated Immunosuppression and Potentiates CD8+ T-Cell-Induced Killing of Chronic Lymphocytic Leukemia (CLL) Cells Ex Vivo

Alak Manna, PhD, Sharoon Akhtar, MPhil, Paul Yi, BS, Sameer A. Parikh, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Victoria R. Alegria, Taimur Sher, MD, Fabio Malavasi, MD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2017) 130 (Supplement 1): 1736.

https://doi.org/10.1182/blood.V130.Suppl_1.1736.1736

Published: 2017

Journal Articles

CD38 and Antibody Therapy: What Can Basic Science Add?

Fabio Malavasi, MD, Antonella Chillemi, PhD, Barbara Castella, PhD, Ilaria Schiavoni, PhD, Danny Incarnato, PhD, Stefania Oliva, MD, Alberto L Horenstein, PhD

Blood (2016) 128 (22): SCI-36.

https://doi.org/10.1182/blood.V128.22.SCI-36.SCI-36

Published: 2016

Journal Articles

Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells

Antonella Chillemi, PhD, Valeria Quarona, Andrea Zito, Fabio Morandi, PhD, Danilo Marimpietri, Massimiliano Cuccioloni, PhD, Oldham J Robert, Cragg S Mark, PhD, Marina Bolzoni, PhD, Denise Toscani, PhD, Vito Pistoia, MD, Nicola Giuliani, MD PhD, Alberto L Horenstein, PhD, Kate Sasser, PhD, Fabio Malavasi, MD

Blood (2015) 126 (23): 1849.

https://doi.org/10.1182/blood.V126.23.1849.1849

Published: 2015

Journal Articles

Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity

Denise Toscani, PhD, Marina Bolzoni, PhD, Federica Costa, Valeria Quarona, Valentina Marchica, Cristina Mancini, MD, Eugenia Martella, MD, Sabrina Bonomini, Paola Storti, PhD, Antonella Chillemi, PhD, Fabrizio Accardi, MD, Benedetta Dalla Palma, MD, Luisa Craviotto, MD, Fabio Malavasi, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2015) 126 (23): 2959.

https://doi.org/10.1182/blood.V126.23.2959.2959

Published: 2015

Journal Articles

Ectoenzymes and Their Products As Communicators in the Human Myeloma Niche

Alberto L. Horenstein, PhD, Valentina Ferri, Marina Bolzoni, Valeria Quarona, Antonella Chillemi, Gianluca Zaccarello, Nicola Giuliani, MD PhD, Fabio Malavasi, MD PhD

Blood (2014) 124 (21): 2064.

https://doi.org/10.1182/blood.V124.21.2064.2064

Published: 2014

Journal Articles

CCR4: TARC Interaction Provides Supplementary Pro-Survival and Proliferative Signals to Chronic Lymphocytic Leukemia Cells.

Rajendra N Damle, PhD, Sonal Temburni, Matthew Kaufman, MD, Jonathan E. Kolitz, MD, Steven L. Allen, Fabio Malavasi, MD, Kanti R. Rai, MD, Nicholas Chiorazzi, MD

Blood (2009) 114 (22): 2327.

https://doi.org/10.1182/blood.V114.22.2327.2327

Published: 2009

Journal Articles

CD38 Induces Homing of Chronic Lymphocytic Leukemia Cells to the Lymphoid Organs through a Functional Interplay with CXCR4.

Silvia Deaglio, MD, PhD, Semra Aydin, MD, Tiziana Vaisitti, PhD, Luciana Bergui, MD, PhD, Davide Rossi, MD, Giovanni D'Arena, MD, Lisa Bonello, PhD, Maurizia Mello Grand, PhD, Giovanna Chiorino, Alberto Horenstein, PhD, Gianluca Gaidano, MD, PhD, Fabio Malavasi, MD

Blood (2009) 114 (22): 2328.

https://doi.org/10.1182/blood.V114.22.2328.2328

Published: 2009

Journal Articles

Host Genetic Background and Risk of Richter Syndrome: The Genotype of LRP4 Is An Independent Predictor of Chronic Lymphocytic Leukemia Transformation to Aggressive Lymphoma.

Davide Rossi, MD, Silvia Rasi, PhD, Claudio Tripodo, MD, Francesco Forconi, MD, PhD, Luca Laurenti, MD, Alessio Bruscaggin, PhD, Marco Fangazio, MD, Alessia Puma, MD, Elisa Sozzi, BSci, Jeffrey T. Malik, MD, Josep F. Nomdedeu, MD, Roberto Marasca, MD, Valter Gattei, MD, Ken H. Young, MD, PhD, Stefano A. Pileri, MD, Francesco Lauria, MD, Fabio Malavasi, MD, PhD, Silvia Deaglio, MD, PhD, Gianluca Gaidano, MD, PhD

Blood (2009) 114 (22): 2340.

https://doi.org/10.1182/blood.V114.22.2340.2340

Published: 2009

Journal Articles

CD38 CD49d Are Physically and Functionally Associated in B-Cell Chronic Lymphocytic Leukemia Cells.

Antonella Zucchetto, Tiziana Vaisitti, Dania Benedetti, Riccardo Bomben, Michele Dal-Bo, Massimo Degan, Giovanni Del Poeta, Valter Gattei, Fabio Malavasi, MD, PhD, Silvia Deaglio, MD, PhD

Blood (2009) 114 (22): 357.

https://doi.org/10.1182/blood.V114.22.357.357

Published: 2009

Journal Articles

Monocytes/Macrophages Are the Major Targets of the CCL3 Chemokine Produced by CD38 + CD49d + Chronic Lymphocytic Leukemia Cells.

Antonella Zucchetto, Dania Benedetti, Claudio Tripodo, MD, Riccardo Bomben, Fleur Bossi, Michele Dal-Bo, Daniela Marconi, Massimo Degan, Giovanni Del Poeta, Silvia Deaglio, Gianluca Gaidano, MD, Francesco Tedesco, Fabio Malavasi, MD, PhD, Valter Gattei, MD

Blood (2009) 114 (22): 2350.

https://doi.org/10.1182/blood.V114.22.2350.2350

Published: 2009

NARROW

CD14 + CD16 + Monocyte Binding to Myeloma Cells Is Required for Daratumumab Dependent Killing in Multiple Myeloma Patients

Daratumumab Mitigates B-Cell Receptor Signaling and Enhances Antitumor Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL) Cells

Precision Targeting of Ion Channel Blocker for the Treatment of AML

Targeting CD38 with Daratumumab Suppresses B-Cell Receptor Signaling and Enhances the Activity of Ibrutinib in Waldenstrom Macroglobulinemia Cells

Daratumumab Decreases Treg-Mediated Immunosuppression and Potentiates CD8+ T-Cell-Induced Killing of Chronic Lymphocytic Leukemia (CLL) Cells Ex Vivo

CD38 and Antibody Therapy: What Can Basic Science Add?

Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells

Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity

Ectoenzymes and Their Products As Communicators in the Human Myeloma Niche

CCR4: TARC Interaction Provides Supplementary Pro-Survival and Proliferative Signals to Chronic Lymphocytic Leukemia Cells.

CD38 Induces Homing of Chronic Lymphocytic Leukemia Cells to the Lymphoid Organs through a Functional Interplay with CXCR4.

Host Genetic Background and Risk of Richter Syndrome: The Genotype of LRP4 Is An Independent Predictor of Chronic Lymphocytic Leukemia Transformation to Aggressive Lymphoma.

CD38 CD49d Are Physically and Functionally Associated in B-Cell Chronic Lymphocytic Leukemia Cells.

Monocytes/Macrophages Are the Major Targets of the CCL3 Chemokine Produced by CD38 + CD49d + Chronic Lymphocytic Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only